Literature DB >> 17873282

Tyr687 dependent APP endocytosis and Abeta production.

Sandra Rebelo1, Sandra Isabel Vieira, Hermann Esselmann, Jens Wiltfang, Edgar F da Cruz e Silva, Odete A B da Cruz e Silva.   

Abstract

The neurotoxic Abeta peptide is derived by proteolytic processing from the Alzheimer's amyloid precursor protein (APP), whose short cytoplasmic domain contains several phosphorylatable amino acids. The latter can be phosphorylated 'in vitro' and 'in vivo,' and in some cases phosphorylation appears to be associated with the disease condition. Using APP-GFP fusion proteins to monitor APP processing, the role of Tyr687 was addressed by mimicking its constitutive phosphorylation (Y687E) and dephosphorylation (Y687F). Contrasting effects on subcellular APP distribution were observed. Y687E-APP-GFP was targeted to the membrane but could not be detected in transferrin containing vesicular structures, and exhibited a concomitant and dramatic decrease in Abeta production. In contrast, Y687F-APP-GFP was endocytosed similarly to wild type APP, but was relatively favoured for beta-secretase cleavage. Overall, Tyr687 appears to be a critical residue determining APP targeting and processing via different pathways, including endocytosis and retrograde transport. Significantly, from a disease perspective, mimicking Tyr687 phosphorylation resulted in a hitherto undescribed inhibition of Abeta production. Our results provide novel insights into the role of direct APP phosphorylation on APP targeting, processing and Abeta production.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873282     DOI: 10.1007/s12031-007-0001-z

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  39 in total

1.  Transient structure of the amyloid precursor protein cytoplasmic tail indicates preordering of structure for binding to cytosolic factors.

Authors:  T A Ramelot; L N Gentile; L K Nicholson
Journal:  Biochemistry       Date:  2000-03-14       Impact factor: 3.162

2.  Solution conformations of a peptide containing the cytoplasmic domain sequence of the beta amyloid precursor protein.

Authors:  C D Kroenke; D Ziemnicka-Kotula; J Xu; L Kotula; A G Palmer
Journal:  Biochemistry       Date:  1997-07-01       Impact factor: 3.162

3.  The intracellular cytoplasmic domain of the Alzheimer's disease amyloid precursor protein interacts with phosphotyrosine-binding domain proteins in the yeast two-hybrid system.

Authors:  D M McLoughlin; C C Miller
Journal:  FEBS Lett       Date:  1996-11-18       Impact factor: 4.124

4.  cDNA cloning and chromosome mapping of the human Fe65 gene: interaction of the conserved cytoplasmic domains of the human beta-amyloid precursor protein and its homologues with the mouse Fe65 protein.

Authors:  S L Bressler; M D Gray; B L Sopher; Q Hu; M G Hearn; D G Pham; M B Dinulos; K Fukuchi; S S Sisodia; M A Miller; C M Disteche; G M Martin
Journal:  Hum Mol Genet       Date:  1996-10       Impact factor: 6.150

5.  Evidence that production and release of amyloid beta-protein involves the endocytic pathway.

Authors:  E H Koo; S L Squazzo
Journal:  J Biol Chem       Date:  1994-07-01       Impact factor: 5.157

6.  Mammalian APH-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-beta precursor protein and Notch.

Authors:  Sheu-Fen Lee; Sanjiv Shah; Hongqiao Li; Cong Yu; Weiping Han; Gang Yu
Journal:  J Biol Chem       Date:  2002-09-23       Impact factor: 5.157

7.  The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement.

Authors:  S L Sabo; A F Ikin; J D Buxbaum; P Greengard
Journal:  J Cell Biol       Date:  2001-06-25       Impact factor: 10.539

8.  Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1.

Authors:  Y M Li; M Xu; M T Lai; Q Huang; J L Castro; J DiMuzio-Mower; T Harrison; C Lellis; A Nadin; J G Neduvelil; R B Register; M K Sardana; M S Shearman; A L Smith; X P Shi; K C Yin; J A Shafer; S J Gardell
Journal:  Nature       Date:  2000-06-08       Impact factor: 49.962

9.  AP-2/Eps15 interaction is required for receptor-mediated endocytosis.

Authors:  A Benmerah; C Lamaze; B Bègue; S L Schmid; A Dautry-Varsat; N Cerf-Bensussan
Journal:  J Cell Biol       Date:  1998-03-09       Impact factor: 10.539

10.  APP processing is regulated by cytoplasmic phosphorylation.

Authors:  Ming-Sum Lee; Shih-Chu Kao; Cynthia A Lemere; Weiming Xia; Huang-Chun Tseng; Ying Zhou; Rachael Neve; Michael K Ahlijanian; Li-Huei Tsai
Journal:  J Cell Biol       Date:  2003-10-13       Impact factor: 10.539

View more
  16 in total

Review 1.  Aβ Influences Cytoskeletal Signaling Cascades with Consequences to Alzheimer's Disease.

Authors:  Ana Gabriela Henriques; Joana Machado Oliveira; Liliana Patrícia Carvalho; Odete A B da Cruz E Silva
Journal:  Mol Neurobiol       Date:  2014-10-26       Impact factor: 5.590

Review 2.  Golgi defects enhance APP amyloidogenic processing in Alzheimer's disease.

Authors:  Gunjan Joshi; Yanzhuang Wang
Journal:  Bioessays       Date:  2014-12-28       Impact factor: 4.345

3.  Induced dimerization of the amyloid precursor protein leads to decreased amyloid-beta protein production.

Authors:  Simone Eggert; Brea Midthune; Barbara Cottrell; Edward H Koo
Journal:  J Biol Chem       Date:  2009-07-13       Impact factor: 5.157

4.  LAP1 is a crucial protein for the maintenance of the nuclear envelope structure and cell cycle progression.

Authors:  Mariana Santos; Patrícia Costa; Filipa Martins; Edgar F da Cruz e Silva; Odete A B da Cruz e Silva; Sandra Rebelo
Journal:  Mol Cell Biochem       Date:  2014-10-17       Impact factor: 3.396

5.  Retrieval of the Alzheimer's amyloid precursor protein from the endosome to the TGN is S655 phosphorylation state-dependent and retromer-mediated.

Authors:  Sandra I Vieira; Sandra Rebelo; Hermann Esselmann; Jens Wiltfang; James Lah; Rachel Lane; Scott A Small; Sam Gandy; Edgar F da Cruz E Silva; Odete Ab da Cruz E Silva
Journal:  Mol Neurodegener       Date:  2010-10-11       Impact factor: 14.195

6.  Alphabeta hinders nuclear targeting of AICD and Fe65 in primary neuronal cultures.

Authors:  A G Henriques; S I Vieira; E F da Cruz e Silva; O A B da Cruz e Silva
Journal:  J Mol Neurosci       Date:  2009-04-02       Impact factor: 3.444

7.  S655 phosphorylation enhances APP secretory traffic.

Authors:  Sandra Isabel Vieira; Sandra Rebelo; Sara Catarina Domingues; Edgar F da Cruz e Silva; Odete A B da Cruz e Silva
Journal:  Mol Cell Biochem       Date:  2009-04-21       Impact factor: 3.396

8.  TrkB receptor cleavage by delta-secretase abolishes its phosphorylation of APP, aggravating Alzheimer's disease pathologies.

Authors:  Yiyuan Xia; Zhi-Hao Wang; Pai Liu; Laura Edgington-Mitchell; Xia Liu; Xiao-Chuan Wang; Keqiang Ye
Journal:  Mol Psychiatry       Date:  2020-08-11       Impact factor: 15.992

9.  The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome.

Authors:  Ilaria Zuliani; Chiara Lanzillotta; Antonella Tramutola; Antonio Francioso; Sara Pagnotta; Eugenio Barone; Marzia Perluigi; Fabio Di Domenico
Journal:  Neurotherapeutics       Date:  2020-11-30       Impact factor: 7.620

10.  Protein kinase C and rho activated coiled coil protein kinase 2 (ROCK2) modulate Alzheimer's APP metabolism and phosphorylation of the Vps10-domain protein, SorL1.

Authors:  Rachel F Lane; Joshua W Gatson; Scott A Small; Michelle E Ehrlich; Sam Gandy
Journal:  Mol Neurodegener       Date:  2010-12-30       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.